Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2010

01-10-2010 | Original Article

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia

Authors: Misato Kikuchi, Junji Tanaka, Takeshi Kondo, Satoshi Hashino, Masaharu Kasai, Mitsutoshi Kurosawa, Hiroshi Iwasaki, Masanobu Morioka, Tsugumichi Kawamura, Nobuo Masauzi, Takashi Fukuhara, Yasutaka Kakinoki, Hajime Kobayashi, Satoshi Noto, Masahiro Asaka, Masahiro Imamura

Published in: International Journal of Hematology | Issue 3/2010

Login to get access

Abstract

Monitoring minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) is a useful way for assessing treatment response and relapse. We studied the value of MRD and showed a correlation with relapse for 34 adult patients with ALL. MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) with probes derived from fusion chimeric genes (BCR/ABL) (n = 12) or PCR-based detection of clonal immunoglobulin and T cell receptor gene rearrangements (n = 16), or both (n = 6). We analyzed 27 of the 34 patients who could be examined for MRD on day 100 after induction therapy. The overall survival (OS) rate (45.0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in complete remission (CR) patients with MRD level ≥10−3 (n = 12) were significantly lower than those in CR patients with MRD level <10−3 (n = 15) (OS rate 79.0%, RFS rate 79.4%) (log-rank test, P = 0.017 and 0.0007). We also applied multicolor flow cytometry for comparison with MRD results analyzed by PCR methods. The comparison of results obtained in 27 follow-up samples showed consistency in 17 samples (63.0%) (P = 0.057). MRD analysis on day 100 is important for treatment decision in adult ALL.
Literature
1.
Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.CrossRefPubMed
2.
Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The polish adult leukemia group ALL 4-2002 MRD study. Br J Haematol. 2008;142:227–37.CrossRefPubMed
3.
Brüggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24:521–35.CrossRefPubMed
4.
Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol. 2004;112:8–15.CrossRefPubMed
5.
Toubai T, Tanaka J, Ota S, Fukuhara T, Hashino S, Kondo T, et al. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol. 2005;80:181–7.CrossRefPubMed
6.
Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97:2115–20.CrossRefPubMed
7.
Mortuza FY, Papaioannou M, Moreira IM, Coyle LA, Gameiro P, Gandini D, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094–104.CrossRefPubMed
8.
Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia. 2007;21:622–6.PubMed
9.
Brüggemann M, Pott C, Ritgen M, Kneba M. Significance of minimal residual disease in lymphoid malignancies. Acta Haematol. 2004;112:111–9.CrossRefPubMed
10.
Foroni L, Hoffbrand AV. Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15:71–90.CrossRefPubMed
11.
Szczepański T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood. 2002;99:2315–23.CrossRefPubMed
12.
Brisco J, Hughes E, Neoh SH, Sykes PJ, Bradstock K, Enno A, et al. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood. 1996;87:5251–6.PubMed
13.
Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood. 1997;89:2602–9.PubMed
14.
Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol. 2005;128:774–82.CrossRefPubMed
15.
Robillard N, Cavé H, Méchinaud F, Guidal C, Garnache-Ottou F, Rohrlich PS, et al. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia. Haematologica. 2005;90:1516–23.PubMed
16.
Neale GA, Coustan-Smith E, Stow P, Pan Q, Chen X, Pui CH, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18:934–8.CrossRefPubMed
17.
Sánchez J, Serrano J, Gómez P, Martínez F, Martín C, Madero L, et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol. 2002;116:686–94.CrossRefPubMed
18.
Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612–8.CrossRefPubMed
19.
Patel B, Rai L, Buck G, Richards SM, Mortuza Y, Mitchell W, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol. 2010;148:80–9.CrossRefPubMed
20.
Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin N Am. 2009;23:1083–98.CrossRef
21.
Thörn I, Botling J, Hermansson M, Lönnerholm G, Sundström C, Rosenquist R, et al. Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia. Leuk Res. 2009;33:1047–54.CrossRefPubMed
22.
Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol. 2009;46:100–6.CrossRefPubMed
Metadata
Title
Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia
Authors
Misato Kikuchi
Junji Tanaka
Takeshi Kondo
Satoshi Hashino
Masaharu Kasai
Mitsutoshi Kurosawa
Hiroshi Iwasaki
Masanobu Morioka
Tsugumichi Kawamura
Nobuo Masauzi
Takashi Fukuhara
Yasutaka Kakinoki
Hajime Kobayashi
Satoshi Noto
Masahiro Asaka
Masahiro Imamura
Publication date
01-10-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0670-1

Other articles of this Issue 3/2010

International Journal of Hematology 3/2010 Go to the issue

Original Article

Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience

Letter to the Editor

Hemophagocytic lymphohistiocytosis associated with myelodysplastic syndromes

Case Report

Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

Letter to the Editor

Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate

Progress in Hematology

Congenital dyserythropoietic anemia

Progress in Hematology

Recent progress in dyskeratosis congenita
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits